{"doi":"10.1007/s10557-021-07174-2","title":"Effects of Angiotensin Receptor-Neprilysin Inhibitor in Arrhythmogenicity Following Left Atrial Appendage Closure in an Animal Model","abstract":null,"journal":"Cardiovascular Drugs and Therapy","year":2021,"id":621824,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1605971,"name":"Isaiah C. Lugtu","orcid":null,"position":1,"is_corresponding":false},{"id":1605972,"name":"Shih-Lin Chang","orcid":null,"position":2,"is_corresponding":false},{"id":1605973,"name":"Shin-Huei Liu","orcid":null,"position":3,"is_corresponding":false},{"id":1605974,"name":"Shih-Ann Chen","orcid":null,"position":4,"is_corresponding":false},{"id":1605976,"name":"Li-Wei Lo","orcid":"0000-0001-9102-227X","position":5,"is_corresponding":false},{"id":1605970,"name":"Wen-Han Cheng","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Effects of Angiotensin Receptor-Neprilysin Inhibitor in Arrhythmogenicity Following Left Atrial Appendage Closure in an Animal Model","abstract":"<h4>Purpose</h4>Left atrial appendage (LAA) closure decreases atrial natriuretic peptide (ANP) levels, which indirectly increases the risk of arrhythmogenicity. We aimed to determine the effect of a combined angiotensin receptor-neprilysin inhibitor (ARNi) on arrhythmogenicity following LAA closure in an animal model.<h4>Methods</h4>Twenty-four rabbits were randomized into four groups: (1) control, (2) LAA closure (LAAC), (3) heart failure (HF)-LAAC, and (4) HF-LAAC with sacubitril/valsartan (+ARNi). HF models were developed in the HF-LAAC and HF-LAAC+ARNi groups. Epicardial LAA exclusion was performed in the LAAC, HF-LAAC, and HF-LAAC+ARNi groups. ANP levels were measured. An electrophysiological study was performed. The myocardium was harvested for histopathological analysis.<h4>Results</h4>The ANP level decreased in the LAAC group (785 ± 103 pg/mL, p = 0.03), failed to increase in the HF-LAAC group (917 ± 172 pg/mL, p = 0.3), and increased in the HF-LAAC+ARNi group (1524 ± 126 pg/mL, p < 0.01) compared to that in the control group (1014 ± 56 pg/mL). The atrial effective refractory period (ERP) was prolonged in the HF-LAAC group and restored to baseline in the HF-LAAC+ARNi group. Ventricular ERP was the longest in the HF-LAAC group. The atrial fibrillation window of vulnerability (AF WOV) was elevated in the LAAC, HF-LAAC, and HF-LAAC+ARNi groups, with the latter group having lower AF WOV than the two former groups. Ventricular fibrillation (VF) inducibility was the highest in the HF-LAAC group (51 ± 5%, p < 0.001), followed by the LAAC group (30 ± 4%, p = 0.006) and the HF-LAAC+ARNi group (25 ± 5%, p = 0.11) when compared to the control group (18 ± 4%). Atrial and ventricular fibrosis were noted in all groups except the control group.<h4>Conclusion</h4>LAA closure decreased ANP, which in turn increased AF and VF inducibility. Atrial and ventricular arrhythmogenicity was suppressed by ARNi.","is_dataset_classified":null,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33818689","pmcid":null,"openalex_id":"https://openalex.org/W3144879260","authors":[],"funders":[{"funder_name":"Ministry of Science and Technology","grant_id":"MOST107‐2314‐B‐075‐065‐MY3; MOST108-2314-B-010 -051 -MY3","title":null},{"funder_name":"Taipei Veterans General Hospital","grant_id":"V108C‐073, V109C-001, VGHUST107‐G1‐8‐1","title":null},{"funder_name":"Ministry of Science and Technology","grant_id":"MOST107-2314-B-075-065-MY3; MOST108-2314-B-010 -051 -MY3","title":null},{"funder_name":"Taipei Veterans General Hospital","grant_id":"V108C-073, V109C-001, VGHUST107-G1-8-1","title":null}],"total_grants":4,"fwci":1.4609,"citation_percentile":0.83106395,"influential_citations":0,"citation_trend":[{"year":2021,"count":2},{"year":2022,"count":2},{"year":2023,"count":2},{"year":2024,"count":4},{"year":2025,"count":1}],"oa_status":"closed","license":"https://www.springer.com/tdm","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007/s10557-021-07174-2.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s10557-021-07174-2/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1007/s10557-021-07174-2","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33818689","host_type":"repository"}],"fields_of_study":["Atrial Fibrillation Management and Outcomes","Cardiac Arrhythmias and Treatments","Cardiovascular Function and Risk Factors","Aminobutyrates","Angiotensin Receptor Antagonists","Animals","Arrhythmias, Cardiac","Atrial Appendage","Atrial Natriuretic Factor","Biphenyl Compounds","Drug Combinations","Heart Atria","Models, Animal","Neprilysin","Rabbits","Septal Occluder Device","Treatment Outcome","Valsartan"],"mesh_terms":["Valsartan","Aminobutyrates","Animals","Arrhythmias, Cardiac","Biphenyl Compounds","Drug Combinations","Heart Atria","Atrial Natriuretic Factor","Rabbits","Neprilysin","Treatment Outcome","Atrial Appendage","Models, Animal","Septal Occluder Device","Angiotensin Receptor Antagonists"],"keywords":["Internal medicine","Cardiology","Medicine","Valsartan","Sacubitril","Atrial fibrillation","Heart failure","Ejection fraction","Blood pressure","Left Atrial Appendage Closure","Atrial Arrhythmogenicity","Angiotensin Receptor Neprilysin Inhibition","Ventricular Arrhythmogenicity"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T16:14:30.481860Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}